Skip to content
BD4BO

BD4BO

Big Data for Better Outcomes

  • What is BD4BO
    • About BD4BO
    • Projects
    • Partners
    • About Big Data
  • Why BD4BO
    • Program Summary
    • Q and A
    • Mission statement and Key aspects
  • News & Events
    • News
    • Events
  • Publications
  • Contact us
  • Login
  • Knowledge Hub

New publication: Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease

November 28, 2018December 5, 2018 imi2_admin

Although there are a growing number of well-reported, late-stage clinical trial failures in Alzheimer’s disease, the introduction of a disease-modifying therapy within the next 5 years may be anticipated.

read more

News

Post navigation

Jonathan Pearce, Lymphoma Coalition, about the importance of the patient perspective in HARMONY
Please listen to Maurille Feudjo Tepie of HARMONY Partner AMGEN, addressing BigData and the value for society.
BD4BO
Big Data for Better Outcomes
This website has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2) under grant agreement No. 116055. This Joint Undertaking receives support from the European Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA). Contact for BD4BO Website
Semmelweis University – Health Services Management Training Centre, Budapest
Email: doit.communication@emk.sote.hu
Legal notice